Cyxone's cyclotide study into inflammatory bowel disease starts at Medical University of Vienna
January 31, 2018 10:42 (CET)
In response to interest from drug companies, Cyxone is to review whether cyclotides are effective against inflammatory bowel disease (IBD). The study was planned by the Medical University of Vienna and is now underway.
Investigating the effects of cyclotides on IBD has become more relevant following Cyxone's discovery that the company's cyclotide T20K appears to accumulate in the intestine, the organ affected by IBD.
Cyxone is following the IBD study with considerable interest. The study is expected to report in March this year. The company will then review the results of the study, and decide whether to include IBD in its strategy going forward.
IBD is an inflammatory bowel disease that affects some 1.3 milion people worldwide, and for which no treatment currently exists.
30 January 2018
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
211 22 Malmö
About Cyxone Press release (PDF)
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of substances that inhibit key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000.